QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 cisco-to-rally-around-24-here-are-10-top-analyst-forecasts-for-monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 oppenheimer-reiterates-outperform-on-veru-lowers-price-target-to-5

Oppenheimer analyst Leland Gershell reiterates Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $7 to $5.

 why-jpmorgan-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

 raymond-james-initiates-coverage-on-veru-with-outperform-rating-announces-price-target-of-3

Raymond James analyst Gary Nachman initiates coverage on Veru (NASDAQ:VERU) with a Outperform rating and announces Price Tar...

 hc-wainwright--co-reiterates-buy-on-veru-maintains-2-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Veru (NASDAQ:VERU) with a Buy and maintains $2 price target.

 veru-q1-sales-210m-miss-520m-estimate

Veru (NASDAQ:VERU) reported quarterly sales of $2.10 million which missed the analyst consensus estimate of $5.20 million by 59...

 earnings-scheduled-for-february-8-2024

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share ...

 veru-announces-fda-clearance-of-ind-application-for-phase-2b-clinical-trial-with-enobosarm-to-treat-muscle-loss-associated-with-weight-loss-drugs

FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially ...

 veru-inc-13g-filing-shows-adage-capital-partners-lp-reported-a-95-stake-in-the-co-as-of-december-14-2023

- SEC Filing

 veru-to-host-investor-call-on-january-4th-2024-to-discuss-recent-financing-and-strategy-to-prioritize-the-development-of-enobosarm-as-a-combination-treatment-to-prevent-muscle-loss-and-augment-fat-loss-associated-with-weight-loss-glp-1-drugs

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatmen...

 veru-announced-today-the-pricing-of-an-33m-underwritten-public-offering-of-45833333-shares-of-its-common-stock-at-a-price-to-the-public-of-072share

Veru intends to use the net proceeds from the offering to fund its clinical stage drug development with a primary near-term foc...

 why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 311 stocks hit new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION